These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 26449250)

  • 1. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
    Butowski N; Colman H; De Groot JF; Omuro AM; Nayak L; Wen PY; Cloughesy TF; Marimuthu A; Haidar S; Perry A; Huse J; Phillips J; West BL; Nolop KB; Hsu HH; Ligon KL; Molinaro AM; Prados M
    Neuro Oncol; 2016 Apr; 18(4):557-64. PubMed ID: 26449250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.
    Tien AC; Li J; Bao X; Derogatis A; Kim S; Mehta S; Sanai N
    Clin Cancer Res; 2019 Oct; 25(19):5777-5786. PubMed ID: 31285369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.
    Lee JH; Chen TW; Hsu CH; Yen YH; Yang JC; Cheng AL; Sasaki SI; Chiu LL; Sugihara M; Ishizuka T; Oguma T; Tajima N; Lin CC
    Invest New Drugs; 2020 Feb; 38(1):99-110. PubMed ID: 30825104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
    Miller TW; Traphagen NA; Li J; Lewis LD; Lopes B; Asthagiri A; Loomba J; De Jong J; Schiff D; Patel SH; Purow BW; Fadul CE
    J Neurooncol; 2019 Sep; 144(3):563-572. PubMed ID: 31399936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
    Tap WD; Wainberg ZA; Anthony SP; Ibrahim PN; Zhang C; Healey JH; Chmielowski B; Staddon AP; Cohn AL; Shapiro GI; Keedy VL; Singh AS; Puzanov I; Kwak EL; Wagner AJ; Von Hoff DD; Weiss GJ; Ramanathan RK; Zhang J; Habets G; Zhang Y; Burton EA; Visor G; Sanftner L; Severson P; Nguyen H; Kim MJ; Marimuthu A; Tsang G; Shellooe R; Gee C; West BL; Hirth P; Nolop K; van de Rijn M; Hsu HH; Peterfy C; Lin PS; Tong-Starksen S; Bollag G
    N Engl J Med; 2015 Jul; 373(5):428-37. PubMed ID: 26222558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
    Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
    Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).
    Hutterer M; Nowosielski M; Haybaeck J; Embacher S; Stockhammer F; Gotwald T; Holzner B; Capper D; Preusser M; Marosi C; Oberndorfer S; Moik M; Buchroithner J; Seiz M; Tuettenberg J; Herrlinger U; Wick A; Vajkoczy P; Stockhammer G
    Neuro Oncol; 2014 Jan; 16(1):92-102. PubMed ID: 24311637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
    Wen PY; Touat M; Alexander BM; Mellinghoff IK; Ramkissoon S; McCluskey CS; Pelton K; Haidar S; Basu SS; Gaffey SC; Brown LE; Martinez-Ledesma JE; Wu S; Kim J; Wei W; Park MA; Huse JT; Kuhn JG; Rinne ML; Colman H; Agar NYR; Omuro AM; DeAngelis LM; Gilbert MR; de Groot JF; Cloughesy TF; Chi AS; Roberts TM; Zhao JJ; Lee EQ; Nayak L; Heath JR; Horky LL; Batchelor TT; Beroukhim R; Chang SM; Ligon AH; Dunn IF; Koul D; Young GS; Prados MD; Reardon DA; Yung WKA; Ligon KL
    J Clin Oncol; 2019 Mar; 37(9):741-750. PubMed ID: 30715997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
    Ellingson BM; Harris RJ; Woodworth DC; Leu K; Zaw O; Mason WP; Sahebjam S; Abrey LE; Aftab DT; Schwab GM; Hessel C; Lai A; Nghiemphu PL; Pope WB; Wen PY; Cloughesy TF
    Neuro Oncol; 2017 Jan; 19(1):89-98. PubMed ID: 27580889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous daily sunitinib for recurrent glioblastoma.
    Kreisl TN; Smith P; Sul J; Salgado C; Iwamoto FM; Shih JH; Fine HA
    J Neurooncol; 2013 Jan; 111(1):41-8. PubMed ID: 23086433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
    Kaley TJ; Panageas KS; Mellinghoff IK; Nolan C; Gavrilovic IT; DeAngelis LM; Abrey LE; Holland EC; Lassman AB
    J Neurooncol; 2019 Sep; 144(2):403-407. PubMed ID: 31325145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early posttraumatic CSF1R inhibition via PLX3397 leads to time- and sex-dependent effects on inflammation and neuronal maintenance after traumatic brain injury in mice.
    Wang Y; Wernersbach I; Strehle J; Li S; Appel D; Klein M; Ritter K; Hummel R; Tegeder I; Schäfer MKE
    Brain Behav Immun; 2022 Nov; 106():49-66. PubMed ID: 35933030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098.
    Brown NF; Williams M; Arkenau HT; Fleming RA; Tolson J; Yan L; Zhang J; Singh R; Auger KR; Lenox L; Cox D; Lewis Y; Plisson C; Searle G; Saleem A; Blagden S; Mulholland P
    Neuro Oncol; 2018 Nov; 20(12):1634-1642. PubMed ID: 29788497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
    Wen PY; Chang SM; Lamborn KR; Kuhn JG; Norden AD; Cloughesy TF; Robins HI; Lieberman FS; Gilbert MR; Mehta MP; Drappatz J; Groves MD; Santagata S; Ligon AH; Yung WK; Wright JJ; Dancey J; Aldape KD; Prados MD; Ligon KL
    Neuro Oncol; 2014 Apr; 16(4):567-78. PubMed ID: 24470557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
    Galanis E; Jaeckle KA; Maurer MJ; Reid JM; Ames MM; Hardwick JS; Reilly JF; Loboda A; Nebozhyn M; Fantin VR; Richon VM; Scheithauer B; Giannini C; Flynn PJ; Moore DF; Zwiebel J; Buckner JC
    J Clin Oncol; 2009 Apr; 27(12):2052-8. PubMed ID: 19307505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer's disease.
    Sosna J; Philipp S; Albay R; Reyes-Ruiz JM; Baglietto-Vargas D; LaFerla FM; Glabe CG
    Mol Neurodegener; 2018 Mar; 13(1):11. PubMed ID: 29490706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma.
    Taylor JW; Parikh M; Phillips JJ; James CD; Molinaro AM; Butowski NA; Clarke JL; Oberheim-Bush NA; Chang SM; Berger MS; Prados M
    J Neurooncol; 2018 Nov; 140(2):477-483. PubMed ID: 30151703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF1R inhibitor PLX3397 depletes microglia in Mongolian gerbil Meriones unguiculatus, but not in syrian hamster Mesocricetus auratus.
    Sato RY; Zhang Y; Kotake KT; Onishi H; Ito S; Norimoto H; Zhou Z
    J Pharmacol Sci; 2024 Jun; 155(2):29-34. PubMed ID: 38677783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microglial repopulation induced by PLX3397 protects against ischemic brain injury by suppressing neuroinflammation in aged mice.
    Li X; Shan J; Liu X; Huang Z; Xu G; Ren L
    Int Immunopharmacol; 2024 Sep; 138():112473. PubMed ID: 38943977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization.
    Stafford JH; Hirai T; Deng L; Chernikova SB; Urata K; West BL; Brown JM
    Neuro Oncol; 2016 Jun; 18(6):797-806. PubMed ID: 26538619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.